Genomic Health, Inc. Forecasted to Earn Q3 2018 Earnings of $0.06 Per Share (GHDX)

Share on StockTwits

Genomic Health, Inc. (NASDAQ:GHDX) – Equities research analysts at Jefferies Financial Group cut their Q3 2018 EPS estimates for shares of Genomic Health in a research note issued to investors on Friday, August 3rd, Zacks Investment Research reports. Jefferies Financial Group analyst B. Couillard now forecasts that the medical research company will earn $0.06 per share for the quarter, down from their prior estimate of $0.11. Jefferies Financial Group currently has a “Hold” rating and a $50.00 target price on the stock. Jefferies Financial Group also issued estimates for Genomic Health’s FY2018 earnings at $0.46 EPS, Q1 2019 earnings at $0.20 EPS, Q2 2019 earnings at $0.20 EPS, Q3 2019 earnings at $0.20 EPS, FY2019 earnings at $0.80 EPS and FY2020 earnings at $1.00 EPS.

Several other analysts also recently issued reports on GHDX. Deutsche Bank lifted their target price on Genomic Health from $32.00 to $34.00 and gave the company a “hold” rating in a research note on Thursday, May 3rd. ValuEngine raised Genomic Health from a “sell” rating to a “hold” rating in a research note on Thursday, May 3rd. Zacks Investment Research raised Genomic Health from a “hold” rating to a “strong-buy” rating and set a $42.00 target price on the stock in a research note on Wednesday, May 9th. BidaskClub raised Genomic Health from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 12th. Finally, Canaccord Genuity lifted their target price on Genomic Health from $41.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, June 4th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, two have assigned a buy rating and two have assigned a strong buy rating to the company. Genomic Health currently has a consensus rating of “Hold” and an average price target of $45.44.

GHDX traded up $0.79 on Monday, hitting $60.29. 236,600 shares of the company’s stock traded hands, compared to its average volume of 255,146. The company has a market capitalization of $2.07 billion, a PE ratio of 6,087.00 and a beta of 0.49. Genomic Health has a one year low of $26.54 and a one year high of $62.25.

Genomic Health (NASDAQ:GHDX) last posted its quarterly earnings data on Thursday, August 2nd. The medical research company reported $0.26 EPS for the quarter, topping the consensus estimate of $0.07 by $0.19. The firm had revenue of $95.60 million for the quarter, compared to the consensus estimate of $92.23 million. Genomic Health had a return on equity of 9.09% and a net margin of 1.18%. The business’s revenue for the quarter was up 14.1% compared to the same quarter last year. During the same quarter last year, the company earned ($0.08) earnings per share.

In other news, insider Kimberly J. Popovits sold 60,000 shares of Genomic Health stock in a transaction that occurred on Tuesday, August 14th. The stock was sold at an average price of $52.60, for a total value of $3,156,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO G Bradley Cole sold 8,529 shares of Genomic Health stock in a transaction that occurred on Thursday, August 9th. The stock was sold at an average price of $55.94, for a total value of $477,112.26. The disclosure for this sale can be found here. Insiders have sold a total of 206,693 shares of company stock valued at $10,251,425 in the last 90 days. 45.80% of the stock is currently owned by company insiders.

Several institutional investors have recently made changes to their positions in GHDX. BlackRock Inc. boosted its holdings in Genomic Health by 3.6% during the 2nd quarter. BlackRock Inc. now owns 2,002,972 shares of the medical research company’s stock valued at $100,949,000 after acquiring an additional 68,691 shares during the period. Millennium Management LLC boosted its holdings in Genomic Health by 114.0% during the 2nd quarter. Millennium Management LLC now owns 1,446,250 shares of the medical research company’s stock valued at $72,891,000 after acquiring an additional 770,413 shares during the period. Renaissance Technologies LLC boosted its holdings in Genomic Health by 18.8% during the 2nd quarter. Renaissance Technologies LLC now owns 1,404,924 shares of the medical research company’s stock valued at $70,808,000 after acquiring an additional 222,324 shares during the period. Point72 Asset Management L.P. boosted its holdings in Genomic Health by 136.0% during the 1st quarter. Point72 Asset Management L.P. now owns 388,400 shares of the medical research company’s stock valued at $12,153,000 after acquiring an additional 223,800 shares during the period. Finally, Northern Trust Corp boosted its holdings in Genomic Health by 0.6% during the 1st quarter. Northern Trust Corp now owns 269,424 shares of the medical research company’s stock valued at $8,430,000 after acquiring an additional 1,608 shares during the period. Hedge funds and other institutional investors own 89.33% of the company’s stock.

About Genomic Health

Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.

Read More: NASDAQ

Get a free copy of the Zacks research report on Genomic Health (GHDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.